Anneveldt Kimberley J, van 't Oever Heleen J, Verpalen Inez M, Nijholt Ingrid M, Bartels Wilbert, Dijkstra Jeroen R, van den Hoed Rolf D, van 't Veer-Ten Kate Miranda, de Boer Erwin, Veersema Sebastiaan, Huirne Judith A F, Schutte Joke M, Boomsma Martijn F
Department of Radiology, Isala hospital, Dokter van Heesweg 2, 8025 AB Zwolle, The Netherlands.
Department of Gynecology, Isala hospital, Dokter van Heesweg 2, 8025 AB Zwolle, The Netherlands.
Eur J Radiol Open. 2022 Mar 21;9:100413. doi: 10.1016/j.ejro.2022.100413. eCollection 2022.
We investigated whether administration of the long-acting uterus stimulant carbetocin increased intra-subject sonication efficiency during Magnetic Resonance image guided High Intensity Focused Ultrasound (MR-HIFU) treatment of uterine fibroids.
In this prospective cohort study, thirty women with symptomatic uterine fibroids undergoing MR-HIFU treatment were included between January 2018 and January 2019. Treatment started with three sonications on one side of the uterine fibroid. Subsequently, one ampoule of 1 mL carbetocin (100 µg/mL) was administered intravenously and treatment continued with three sonications on the other side of the uterine fibroid. We compared the intra-subject sonication efficiency, in terms of Energy Efficiency Factor (EEF), thermal dose volume and sonication time to ablate one cm of fibroid tissue, before and after carbetocin administration. Adverse events that occurred within 30 min after carbetocin administration were recorded.
Sonication efficiency improved after carbetocin administration as indicated by a significant decrease in EEF and sonication time (p = 0.006 and p = 0.001 respectively), and a significant increase in thermal dose volume reached (p = <0.001). Five women (16.7%) experienced temporary tachycardia, one women in combination with headache, within 30 min after carbetocin administration.
Administration of the long-acting uterus stimulant carbetocin improved the MR-HIFU treatment intra-subject sonication efficiency in women with symptomatic uterine fibroids.
我们研究了在磁共振成像引导下高强度聚焦超声（MR-HIFU）治疗子宫肌瘤期间，给予长效子宫兴奋剂卡贝缩宫素是否能提高受试者内部的超声消融效率。
在这项前瞻性队列研究中，纳入了2018年1月至2019年1月期间接受MR-HIFU治疗的30例有症状子宫肌瘤女性。治疗开始时先对子宫肌瘤的一侧进行三次超声消融。随后，静脉注射1支1 mL卡贝缩宫素（100 μg/mL），然后继续对子宫肌瘤的另一侧进行三次超声消融。我们比较了给予卡贝缩宫素前后，受试者内部的超声消融效率，包括能量效率因子（EEF）、热剂量体积以及消融1 cm肌瘤组织所需的超声消融时间。记录卡贝缩宫素给药后30分钟内发生的不良事件。
给予卡贝缩宫素后，超声消融效率有所提高，表现为EEF和超声消融时间显著降低（分别为p = 0.006和p = 0.001），以及达到的热剂量体积显著增加（p = <0.001）。5名女性（16.7%）在卡贝缩宫素给药后30分钟内出现暂时性心动过速，1名女性同时伴有头痛。
给予长效子宫兴奋剂卡贝缩宫素可提高有症状子宫肌瘤女性的MR-HIFU治疗受试者内部超声消融效率。
Zotero 插件